Inhibition of p38 mitogen-activated protein kinase enhances c-Jun N-terminal kinase activity: Implication in inducible nitric oxide synthase expression

BMC Pharmacology

Volumn 6, Issue , 2006, Pages

  Lahti, Aleksi ^a   Sareila, Outi ^a   Kankaanranta, Hannu ^a   Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 ETHYL 2 (4 METHOXYPHENYL) 5 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 ETHYL 2 (4 METHOXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLOHEXIMIDE; IMIDAZOLE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NITRIC OXIDE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; IMMUNOMODULATION; IMMUNOREGULATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA STABILITY; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 33746281656     PISSN: 14712210     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-6-5     Document Type: Article

References (40)

1. Moilanen E, Whittle B, Moncada S: Nitric oxide as a factor in inflammation. In Inflammation: Basic principles and clinical correlates Edited by: Gallin JI, Snyderman R. Philadelphia: Lippincott Williams & Wilkins; 1999:787-800.
2. Korhonen R, Lahti A, Kankaanranta H, Moilanen E: Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 2005, 4:471-479.
3. Alderton WK, Cooper CE, Knowles RG: Nitric oxide synthases: structure, function and inhibition. Biochem J 2001, 357:593-615.
4. Vallance P, Leiper J: Blocking NO synthesis: how, where and why? Nat Rev Drug Discov 2002, 1:939-950.
5. Kleinert H, Schwarz PM, Forstermann U: Regulation of the expression of inducible nitric oxide synthase. Biol Chem 2003, 384:1343-1364.
6. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
7. Dong C, Davis RJ, Flavell RA: MAP kinases in the immune response. Annu Rev Immunol 2002, 20:55-72.
8. Guan Z, Buckman SY, Springer LD, Morrison AR: Both p38alpha(MAPK) and JNK/SAPK pathways are important for induction of nitric-oxide synthase by Interleukin-1beta in rat glomerular mesangial cells. J Biol Chem 1999, 274:36200-36206.
9. Hua LL, Zhao ML, Cosenza M, Kim MO, Huang H, Tanowitz HB, Brosnan CF, Lee SC: Role of mitogen-activated protein kinases in Inducible nitric oxide synthase and TNFalpha expression in human fetal astrocytes. J Neuroimmunol 2002, 126:180-189.
10. Lahti A, Jalonen U, Kankaanranta H, Moilanen E: c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabillzing mRNA in activated macrophages. Mol Pharmacol 2003, 64:308-315.
11. Chen C, Chen YH, Lin WW: Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced INOS and COX-2 expression in J774 macrophages. Immunology 1999, 97:124-129.
12. Chen CC, Wang JK: p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages [published erratum appears in Mol Pharmacol 1999 Jun;55(6):1108]. Mol Pharmacol 1999, 55:481-488.
13. Bhat NR, Feinstein DL, Shen Q, Bhat AN: p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells. Roles of nuclear factors, nuclear factor kappa B, cAMP response element-binding protein, CCAAT/enhancer-binding protein-beta, and activating transcription factor-2. J Biol Chem 2002, 277:29584-29592.
14. Guan Z, Baier LD, Morrison AR: p38 mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E2 biosynthesis stimulated by interleukin-1beta. J Biol Chem 1997, 272:8083-8089.
15. Chan ED, Riches DW: IFN-gamma + LPS Induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001, 280:C441-C450.
16. Chan ED, Morris KR, Belisle JT, Hill P, Remigio LK, Brennan PJ, Riches DW: Induction of inducible nitric oxide synthase-NO* by lipoarabinomannan of Mycobacterium tuberculosis is mediated by MEKI-ERK, MKK7-JNK, and NF-kappaB signaling pathways. Infect Immun 2001, 69:2001-2010.
17. Chan ED, Winston BW, Uh ST, Wynes MW, Rose DM, Riches DW: Evaluation of the role of mitogen-activated protein kinases in the expression of inducible nitric oxide synthase by IFN-gamma and TNF-alpha in mouse macrophages. J Immunol 1999, 162:415-422.
18. Cho MK, Suh SH, Kim SG: JunB/AP-I and NF-kappa B-mediated induction of nitric oxide synthase by bovine type I collagen in serum-stimulated murine macrophages. Nitric Oxide 2002, 6:319-332.
19. Lahti A, Kankaanranta H, Moilanen E: P38 mitogen-activated protein kinase Inhibitor SB203580 has a bi-directional effect on INOS expression and NO production. Eur J Pharmacol 2002, 454:115-123.
20. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC: SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-I. FEBS Lett 1995, 364:229-233.
21. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacological effects of SB 22 a selective inhibitor of P38 mitogen-activated protein kinase, in anglogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 0025, 284:687-692.
22. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
23. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR: Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997, 235:533-538.
24. Lui P, Zeng C, Acton S, Cok S, Sexton A, Morrison AR: Effects of p38MAPK isoforms on renal mesangial cell inducible nitric oxide synthase expression. Am J Physiol Cell Physiol 2004, 286:C145-C152.
25. Kang KW, Choi SY, Cho MK, Lee CH, Kim SG: Thrombin induces nitric-oxide synthase via Galpha12/13-coupled protein kinase C-dependent I-kappaBalpha phosphorylation and JNK-mediated I-kappaBalpha degradation. J Biol Chem 2003, 278: 17368-17378.
26. Hommes DW, Peppellenbosch MP, van Deventer SJ: Mitogen activated protein (MAP) Kinase signal transduction pathways and novel anti-inflammatory targets. Gut 2003, 52:144-151.
27. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ: JNKI: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994, 76:1025-1037.
28. Newton R, Stevens DA, Hart LA, Lindsay M, Adcock IM, Barnes PJ: Superinduction of COX-2 mRNA by cycloheximide and Interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation. FEBS Lett 1997, 418:135-138.
29. Avdi NJ, Malcolm KC, Nick JA, Worthen GS: A role for protein phosphatase-2A in p38 mitogen-activated protein kinase-mediated regulation of the c-Jun NH(2)-terminal kinase pathway in human neutrophils. J Biol Chem 2002, 277:40687-40696.
30. Keyse SM: Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr Opin Cell Biol 2000, 12:186-192.
31. Rodriguez-Pascual F, Hausding M, Ihrig-Bledert I, Furneaux H, Levy AP. Forstermann U. Kleinert H: Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR. J Biol Chem 2000, 275:26040-26049.
32. Fechir M, Linker K, Pautz A, Hubrich T, Forstermann U, Rodriguez-Pascual F, Kleinert H: Tristetraprolin regulates the expression of the human inducible nitric-oxide synthase gene. Mol Pharmacol 2005, 67:2148-2161.
33. Linker K, Pautz A, Fechir M, Hubrich T, Greeve J, Kleinert H: Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HuR. Nucleic Acids Res 2005, 33:4813-4827.
34. Soderberg M, Raffalli-Mathieu F, Lang MA: Inflammation modulates the interaction of heterogeneous nuclear ribonucleoprotein (hnRNP) l/ polypyrimidine tract: binding protein and hnRNP L with the 3′ untranslated region of the murine inducible nitric-oxide synthase mRNA. Mol Pharmacol 2002, 62:423-431.
35. Korhonen R, Lahti A, Hamalainen M, Kankaanranta H, Moilanen E: Dexamethasone inhibits inducible nitric-oxide synthase expression and nitric oxide production by destabilizing mRNA in lipopolysaccharide-treated macrophages. Mol Pharmacol 2002, 62:698-704.
36. Carpenter L, Cordery D, Biden TJ: Protein kidnase Cdelta activation by interleukin-1beta stabilizes inducible nitric-oxide synthase mRNA in pancreatic beta-cells. J Biol Chem 2001, 276:5368-5374.
37. Gustafsson AB, Brunton LL: beta-adrenergic stimulation of rat cardiac fibroblasts enhances induction of nitric-oxide synthase by interleukin-1beta via message stabilization. Mol Pharmacol 2000, 58:1470-1478.
38. Seiser C, Posch M, Thompson N, Kuhn LC: Effect of transcription inhibitors on the iron-dependent degradation of transferrin receptor mRNA. J Biol Chem 1995, 270:29400-29406.
39. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM: Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 2000, 275:11750-11757.
40. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.